Resveratrol Induces Proteasomal Degradation of PTPN1 to Enhance Cisplatin Sensitivity in Epstein–Barr Virus-Associated Malignancies
Open Access
- 9 April 2026
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (4) , 603
Abstract
Background/Objectives: EBV is an oncogenic virus linked to NPC and GC, driving cisplatin resistance. Resveratrol has anticancer activity, but its targets and mechanisms against EBV-positive cancers remain unclear. Methods: We assessed resveratrol’s cytotoxicity in EBV-positive cells via functional assays, identified targets by chemical similarity search and molecular docking, and validated PTPN1 via in vitro experiments and nude mouse xenograft models. Results: Resveratrol inhibited EBV-positive cell viability in a time- and concentration- dependent manner, with IC50 values ranging from 35.85 to 145.7 μM across different cell lines at 24–72 h. Apoptosis rates increased by approximately 2- to 4-fold after 80 μM resveratrol treatment for 24 h. Resveratrol directly targeted PTPN1 (docking score = −4.89) and promoted its degradation via the proteasome pathway, as MG132 reversed this effect. Notably, resveratrol synergized with cisplatin (combination index < 1) to reverse cisplatin resistance in both in vitro and in vivo models. Furthermore, resveratrol induced EBV lytic reactivation through ROS production, as evidenced by the increased expression of BZLF1, BMRF1, and BALF2, which was attenuated by the ROS scavenger NAC. Conclusions: Our findings identify PTPN1 as a direct anticancer target of resveratrol in EBV-positive cancers. Resveratrol enhances the therapeutic efficacy of cisplatin via PTPN1 proteasomal degradation and induces EBV lytic reactivation through ROS accumulation. These findings provide a mechanistic basis for the development of novel combination therapies targeting EBV-associated malignancies.Keywords
Funding Information
- National Natural Science Foundation of China (82573064)
- National Natural Science Foundation of China (82303137)
- National Natural Science Foundation of China (82073030)
- Natural Science Foundation of Hunan Province (2025JJ60499)
- Natural Science Foundation of Hunan Province (2022JJ20083)
- Hunan Provincial Postgraduate Research and Innovation Project (CX20250184)
- Central South University (2025ZZTS0234)
This publication has 64 references indexed in Scilit:
- Discovery of novel oleanolic acid glycoside derivatives targeting PTP1B/PI3K/AKT signaling pathway for the treatment of breast cancerBioorganic Chemistry, 2025
- Epstein Barr virus: A cellular hijacker in cancerBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2024
- Resveratrol suppresses liver cancer progression by downregulating AKR1C3: targeting HCC with HSA nanomaterial as a carrier to enhance therapeutic efficacyApoptosis, 2024
- Resveratrol mediated the proliferation and apoptosis of gastric cancer cells by modulating the PI3K/Akt/P53 signaling pathwayBiochemical and Biophysical Research Communications, 2024
- Resveratrol exhibits diverse anti-cancer activities through epigenetic regulation of E-cadherin and p21 in triple-negative breast cancer cellsBreast Cancer, 2023
- Exosomes loaded with circPARD3 promotes EBV-miR-BART4-induced stemness and cisplatin resistance in nasopharyngeal carcinoma side population cells through the miR-579-3p/SIRT1/SSRP1 axisCell Biology and Toxicology, 2022
- Cisplatin causes covalent inhibition of protein-tyrosine phosphatase 1B (PTP1B) through reaction with its active site cysteine: Molecular, cellular and in vivo mice studiesBiomedicine & Pharmacotherapy, 2022
- Identification of a novel PHGDH covalent inhibitor by chemical proteomics and phenotypic profilingActa Pharmaceutica Sinica B, 2021
- miR‐146b Reverses epithelial‐mesenchymal transition via targeting PTP1B in cisplatin‐resistance human lung adenocarcinoma cellsJournal of Cellular Biochemistry, 2019
- An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cellsCell, 1985